Applying Diagnostic Network Optimisation analysis to inform the introduction of G6PD testing into Indonesia for improved treatment of relapsing malaria

In Indonesia, diagnostic network optimisation suggests equipping 39% (30/76) of facilities in Sumba with G6PD testing devices can cut costs by nearly 30% in year one.

• Why it matters: Radical cure for Plasmodium vivax and Plasmodium ovale requires G6PD screening to avoid haemolysis, but device placement and referral logistics are unclear.
• What they did: OptiDx DNO modelled testing demand using maximum annual malaria cases (2019–2022) across eight districts in Sumba, North Sumatra, and Central Java, comparing baseline universal device coverage with referral-only allocation.
• The result: In Sumba, the 39% device strategy reduced costs by ~30% in the first year and ~20% later, with average referral distance rising from 4.48 km to 9.8 km.

AI summary of the abstract · may contain errors · not medical advice · read the paper.